Selective oestrogen receptor modulationmolecular pharmacology for the millennium

European Journal of Cancer

Volumn 35, Issue 14, 1999, Pages 1974-1985

  Levenson, A S ^a   Jordan, V C ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Breast cancer; Prevention; Raloxifene; Tamoxifen

Indexed keywords

4 (1,2 DIPHENYL 1 BUTENYL)CINNAMIC ACID; 4 HYDROXYTAMOXIFEN; DIETHYLSTILBESTROL; DROLOXIFENE; ESTRADIOL; ESTROGEN; ESTROGEN RECEPTOR; FULVESTRANT; IDOXIFENE; LASOFOXIFENE; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TAMOXIFEN; TOREMIFENE;

ANTINEOPLASTIC ACTIVITY; BREAST CANCER; CANCER INCIDENCE; CANCER PREVENTION; DRUG MECHANISM; DRUG RECEPTOR BINDING; HUMAN; NONHUMAN; POSTMENOPAUSE; PRIORITY JOURNAL; RECEPTOR DENSITY; REVIEW; RISK FACTOR;

EID: 0033372865     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(99)00297-X     Document Type: Article

References (135)

1. Beatson G.T. On the treatment of inoperable cases of carcinoma of the mamma. suggestions for a new method of treatment with illustrative cases Lancet. ii:1896;104-107.
2. Boyd S. On oophorectomy in cancer of the breast. Br. Med. J. ii:1900;1161-1167.
3. Jensen E.V., Jacobson H.I. Basic guides to the mechanism of estrogen action. Recent Prog. Horm. Res. 18:1962;387-414.
4. Toft D., Gorski J. A receptor molecule for estrogens. isolation from the rat uterus and preliminary characterization Proc. Natl. Acad. Sci. USA. 55:1966;1574-1581.
5. Toft D., Shyamala G., Gorski J. A receptor molecule for estrogen. studies using a cell-free system Proc. Natl. Acad. Sci. USA. 57:1967;1740-1743.
6. Gorski J., Toft D., Shyamala G., Smith D., Notides A. Hormone receptors. studies on the interaction of estrogen with the uterus Recent Prog. Horm. Res. 24:1968;45-80.
7. Jensen E.V., Suzuki T., Karashima T., Stumpf W.E., Jungblut P.W., DeSombre E.R. A two step mechanism for the interaction of estradiol with rat uterus. Proc. Natl. Acad. Sci. USA. 59:1968;632-638.
8. Gorski J., Welshons W.V., Sakai D. Remodeling the estrogen receptor model. Mol. Cell Endocrinol. 36:1984;11-15.
9. Jordan V.C., William L. McGuire Memorial Lecture. "Studies on the estrogen receptor in breast cancer"; 20 years as a target for the treatment and prevention of breast cancer. Breast Cancer Res. Treat. 36:1995;267-285.
10. Jordan V.C. B. J. Kennedy Lecture. Estrogen receptor as a target for the prevention of breast cancer. J. Lab. Clin. Med. 133:1999;408-414.
11. Jensen E.V., Jacobson H.I., Smith S., Jungblut P.W., DeSombre E.R. The use of estrogen antagonists in hormone receptor studies. Gynecol. Invest. 3:1972;108-123.
12. Jordan V.C., Koerner S. Tamoxifen (ICI 46, 474) and the human carcinoma 8S estrogen receptor. Eur. J. Cancer. 11A:1975;205-206.
13. Cole M.P., Jones C.T.A., Todd I.D.H. A new antiestrogenic agent in late breast cancer. An early appraisal of ICI 46, 474. Br. J. Cancer. 25:1971;270-275.
14. Ward H.W.C. Antiestrogenic therapy for breast cancer. a trial of tamoxifen at two dose levels Br. Med. J. 1:1973;13-14.
15. Jordan V.C. Laboratory studies to develop general principles for the adjuvant treatment of breast cancer with antiestrogens. problems and potential for future clinical applications Breast Cancer Res. Treat. 3(Suppl.):1983;73-86.
16. Randomized trial of two versus five years of adjuvant tamoxifen for postmenopausal early stage breast cancer. J. Natl. Cancer Inst. 88:1996;1543-1549.
17. Tamoxifen for early breast cancer. an overview of the randomized trials Lancet. 351:1998;1451-1467.
18. Fisher B., Costantino J.P., Wickerham D.L.et al. Tamoxifen for prevention of breast cancer. report of the National Surgical Adjuvant Breast and Bowel Project P-1 study J. Natl. Cancer Inst. 90:1998;1371-1388.
19. Lacassagne A. Hormonal pathogenesis of adenocarcinoma of the breast. Am. J. Cancer. 27:1936;217-225.
20. Jordan V.C. Tamoxifen. the herald of a new era of preventive therapeutics J. Natl. Cancer Inst. 89:1997;747-749.
21. Jordan V.C. Designer estrogens. Scientific Am. 279:1998;60-67.
22. Harper M.J.K., Walpole A.L. A new derivative of triphenylethylene. effect on implantation and mode of action in rats J. Reprod. Fertil. 130:1967;101-119.
23. Terenius L. Structure-activity relationships of antiestrogens with regard to interaction with 17β oestradiol in the mouse uterus and vagina. Acta Endocrinol. (Copenh.). 66(Suppl.):1971;431-447.
24. Lyman S.D., Jordan V.C. Metabolism of nonsteroidal antiestrogens. Jordan V.C. Estrogen/antiestrogen action and breast cancer therapy. 1986;191-219 University of Wisconsin Press, Madison, Wisconsin, USA.
25. Robinson S.P., Langan-Fahey S.M., Jordan V.C. Implications of tamoxifen metabolism in the athymic mouse for the study of antitumor effects upon human breast cancer xenografts. Eur. J. Cancer Clin. Oncol. 25:1989;1769-1776.
26. Robinson S.P., Langan-Fahey S.M., Johnson D.A., Jordan V.C. Metabolites, pharmacodynamics and pharmacokinetics of tamoxifen in rats and mice compared to the breast cancer patient. Drug Metat. Disp. 19:1991;36-43.
27. Levenson A.S., Jordan V.C. MCF-7. the first hormone responsive breast cancer cell line. (Perspectives in Cancer Research) Cancer Res. 57:1997;3071-3078.
28. Osborne C.K., Hobbs K., Clark G.M. Effects of estrogens and antiestrogens on growth of human breast cancer cells in athymic nude mice. Cancer Res. 45:1985;584-590.
29. Jordan V.C., Robinson S.P. Species specific pharmacology of antiestrogens. role of metabolism Fed. Proc. 46:1987;1870-1874.
30. Jordan V.C., Lababidi M.K., Langan-Fahey S. Suppression of mouse mammary tumorigenesis by long-term tamoxifen therapy. J. Natl. Cancer Inst. 83:1991;492-496.
31. Jordan V.C., Lababidi M.K., Mirecki D.M. The anti-oestrogenic and anti-tumour properties of prolonged tamoxifen therapy in C3H/OUJ mice. Eur. J. Cancer. 26A:1990;718-721.
32. Jordan V.C., Phelps E., Lindgren J.U. Effects of antiestrogens on bone in castrated and intact female rats. Breast Cancer Res. Treat. 10:1987;31-35.
33. Gottardis M.M., Jordan V.C. The antitumor actions of keoxifene (raloxifene) and tamoxifen in the N-nitroso-methyl urea - induced rat mammary carcinoma model. Cancer Res. 47:1987;4020-4024.
34. Love R.R., Mazess R.B., Barden H.S.et al. Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer. N. Engl. J. Med. 326:1992;852-856.
35. Delmas P.D., Bjarnason N.H., Mitlak B.H.et al. Effects of raloxifene on bone mineral density, serum cholesterol concentrations and uterine endometrium in postmenopausal women. N. Engl. J. Med. 337:1997;1641-1647.
36. Jordan VC, Glusman JE, Eckert S, et al. Raloxifene reduces incident primary breast cancers. Integrated data from multicenter double blind, placebo controlled randomized trials in postmenopausal women. Breast Cancer Res Treat 1998, 50, 227 (Abstract 2).
37. Gottardis M.M., Robinson S.P., Satyaswwoop P.G., Jordan V.C. Contrasting actions of tamoxifen on endometrial and breast tumor growth in the athymic mouse. Cancer Res. 48:1988;812-815.
38. Assikis V.J., Neven P., Jordan V.C., Vergote I. A realistic clinical perspective of tamoxifen and endometrial carcinogenesis. Eur. J. Cancer. 32A:1996;1464-1476.
39. Green S., Walter P., Kumar V.et al. Human oestrogen receptor cDNA. sequence, expression and homology to v-erb-A Nature. 320:1986;134-139.
40. Greene G.L., Gilna P., Waterfield M., Baker A., Hort Y., Shine J. Sequence and expression of human estrogen receptor complementary DNA. Science. 231:1986;1150-1154.
41. Kuiper G.G.J.M., Enmark E., Pelto-Huikko M., Nilsson S., Gustafsson J-Å. Cloning of a novel estrogen receptor expressed in rat prostate and ovary. Proc. Natl. Acad. Sci. USA. 93:1996;5925-5930.
42. Mosselman S., Polman J., Dijkema R. ERβ identification and characterization of a novel human estrogen receptor FEBS Lett. 392:1996;49-53.
43. Tremblay G.B., Tremblay A., Copeland N.G.et al. Cloning, chromosomal localization, and functional analysis of the murine estrogen receptor β Mol. Endocrinol. 11:1997;353-365.
44. Couse J.F., Korach K.S. Exploring the role of sex steroids through studies of receptor deficient mice. J. Mol. Med. 76:1998;497-511.
45. Kumar V., Green S., Stack G., Berry M., Jin J.R., Chambon P. Functional domains of the human estrogen receptor. Cell. 51:1987;941-951.
46. Montano M.M., Muller V., Trobaugh A., Katzenellenbogen B.S. The carboxy-terminal F domain of the human estrogen receptor. role in the transcriptional activity of the receptor and the effectiveness of antiestrogens as estrogen antagonists Mol. Endocrinol. 9:1995;814-825.
47. Berry M., Metzger D., Chambon P. Role of the two activating domains of the oestrogen receptor in the cell-type and promoter-context dependent agonistic activity of the anti-oestrogen 4-hydroxytamoxifen. EMBO J. 9:1990;2811-2818.
48. Metzger D., Ali S., Bornert J.M., Chambon P. Characterization of the amino-terminal transcriptional activation function of the human estrogen receptor in animal and yeast cells. J. Biol. Chem. 270:1995;9535-9542.
49. Weigel N.L., Zhang Y. Ligand-independent activation of steroid hormone receptors. J. Mol. Med. 76:1998;469-479.
50. Aronica S.M., Katzenellenbogen B.S. Stimulation of estrogen-mediated transcription and alteration in the phosphorylation state of the rat uterine estrogen receptor by estrogen, cyclic adenosine monophosphate, and insulin-like growth factor-1. Mol. Endocrinol. 7:1993;743-752.
51. Bunone G., Briand P-A., Miksicek R.J., Picard D. Activation of the unliganded estrogen receptor by EGF involves the MAP kinase pathway and direct phosphorylation. EMBO J. 15:1996;2174-2183.
52. Kato S., Endoh H., Masuhiro Y.et al. Activation of the estrogen receptor through phosphorylation by mitogen-activated protein kinase. Science. 270:1995;1491-1494.
53. Tremblay G.B., Tremblay A., Labrie F., Giguere V. Dominant activity of activation function 1 (AF-1) and differential stoichiometric requirements for AF-1 and -2 in the estrogen receptor α-β heterodimeric complex. Mol. Cell. Biol. 19:1999;1919-1927.
54. Tremblay A., Tremblay G.B., Labrie F., Giquere V. Ligand-independent recruitment of SRC-1 to estrogen receptor β through phosphorylation of activation function AF-1. Mol. Cell. 3:1999;513-519.
55. Tora L., White J., Brou C.et al. The human estrogen receptor has two independent nonacidic transcriptional activation functions. Cell. 59:1989;477-487.
56. Lees J.A., Fawell S.E., Parker M.G. Identification of two transactivation domains in the mouse oestrogen receptor. Nucleic Acid Res. 17:1989;5477-5487.
57. Wrenn C.K., Katzenellenbogen B.S. Structure-function analysis of the hormone binding domain of the estrogen receptor by region-specific mutagenesis and phenotypic screening in yeast. J. Biol. Chem. 268:1993;24089-24098.
58. Danielian P.S., White R., Lees J.A., Parker M.G. Identification of a conserved region required for hormone dependent transcriptional activation by steroid hormone receptors. EMBO J. 11:1992;1025-1033.
59. Tzukerman M.T., Esty A., Santiso-Mere D.et al. Human estrogen receptor transactivational capacity is determined by both cellular and promoter context and mediated by two functionally distinct intramolecular regions. Mol. Endocrinol. 8:1994;21-30.
60. vom Baur E., Zechel C., Heery D.et al. Differential ligand-dependent interactions between the AF-2 activating domain of nuclear receptors and the putative transcriptional intermediary factors mSUG1 and TIF1. EMBO J. 15:1996;110-124.
61. L'Horset F., Dauvois S., Heery D.M., Cavailles V., Parker M.G. RIP-140 interacts with multiple nuclear receptors by means of two distinct sites. Mol. Cell Biol. 16:1996;6029-6036.
62. Cavailles V., Dauvois S., Danielian P.S., Parker M.G. Interaction of proteins with transcriptionally active ectrogen receptors. Proc. Natl. Acad. Sci. USA. 91:1994;10009-10013.
63. Beato M., Sanchez-Pacheco A. Interaction of steroid hormone receptors with the transcription initiation complex. Endocrine Rev. 17:1996;587-609.
64. Kraus W.L., McInerney E.M., Katzenellenbogen B.S. Ligand-dependent, transcriptionally productive association of the amino- and carboxyl-terminal regions of a steroid hormone nuclear receptor. Proc. Natl. Acad. Sci. USA. 92:1995;12314-12318.
65. Pace P., Tayler J., Suntharalingam S., Coombes R.C., Ali S. Human estrogen receptor β binds DNA in a manner similar to and dimerizes with estrogen receptor α J. Biol. Chem. 272:1997;25832-25838.
66. Paech K., Webb P., Kuiper G.G.J.M.et al. Differential ligand activation of estrogen receptors ERα and ERβ at AP-1 sites. Science. 277:1997;1508-1510.
67. Zou A., Marschke K.B., Arnold K.E.et al. Estrogen receptor β activates the human retinoic acid receptor α-1 promoter in response to tamoxifen and other estrogen receptor antagonists, but not in response to estrogen. Mol. Endocrinol. 13:1999;418-430.
68. Pettersson K., Grandien K., Kuiper G.G.J.M., Gustafsson J.-Å Mouse estrogen receptor β forms estrogen response element-binding heterodimers with estrogen receptor α Mol. Endocrinol. 11:1997;1486-1496.
69. Cowley S.M., Hoare S., Mosselman S., Parker M.G. Estrogen receptors α and β form heterodimers on DNA. J. Biol. Chem. 272:1997;19858-19862.
70. Mitlak B.H., Cohen F.J. Selective estrogen receptor modulators. Drugs. 57:1999;653-663.
71. Horwitz K.B., Jackson T.A., Bain D.L., Richer J.K., Takimoto G.S., Tung L. Nuclear receptor coactivators and corepressors. Mol. Endocrinol. 10:1996;1167-1177.
72. Brzozowski A.M., Pike A.C.W., Dauter Z.et al. Molecular basis of agonism and antagonism in the oestrogen receptor. Nature. 389:1997;753-758.
73. Shiau A.K., Barstad D., Loria P.M.et al. The structural basis of estrogen receptor/coactivator recognition and the antagonism of this interaction by tamoxifen. Cell. 95:1998;927-937.
74. Feng W., Ribeiro R.C., Wagner R.L.et al. Hormone-dependent coactivator binding to a hydrophobic cleft on nuclear receptors. Science. 280:1998;1747-1749.
75. Moras D., Gronemeyer H. The nuclear receptor ligand-binding domain. structure and function Curr. Opin. Cell Biol. 10:1998;384-391.
76. Sadovsky Y., Webb P., Lopez G.et al. Transcriptional activators differ in their responses to overexpression of TATA-box-binding protein. Mol. Cell Biol. 15:1995;1554-1563.
77. Brou C., Wu J., Ali S.et al. Different TBP-associated factors are required for mediating the stimulation of transcription in vitro by the acidic transactivator GAL-VP16 and the two nonacidic activation functions of the estrogen receptor. Nucleic Acids Res. 21:1993;5-12.
78. Ing N.H., Beekman J.M., Tsai S.Y., Tsai M-J., O'Malley B.W. Members of the steroid receptor superfamily interact with TFIIB (S3000-II). J. Biol. Chem. 267:1992;17617-17623.
79. II30 is present in a distinct TFIID complex and is required for transcriptional activation by the estrogen receptor. Cell. 70:1994;107-117.
80. Halachmi S., Marden E., Martin G., MacKay H., Abbondanza C., Brown M. Estrogen receptor-associated proteins. possible mediators of hormone-induced transcription Science. 264:1994;1455-1458.
81. Cavailles V., Dauvois S., L'Horset F.et al. Nuclear factor RIP140 modulates transcriptional activation by the estrogen receptor. EMBO J. 14:1995;3741-3751.
82. Cavailles V., Dauvois S., Danielian P.S., Parker M.G. Interaction of proteins with transcriptionally active estrogen receptors. Proc. Natl. Acad. Sci. USA. 91:1994;10009-10013.
83. Onate S.A., Tsai S.Y., Tsai M-J., O'Malley B.W. Sequence and characterization of a coactivator for the steroid hormone receptor superfamily. Science. 270:1995;1354-1357.
84. Onate S.A., Boonyaratanakornkit V., Spencer T.E.et al. The steroid receptor coactivator-1 contains multiple receptor interacting and activation domains that cooperatively enhance the activation function 1 (AF1) and AF2 domains of steroid receptors. J. Biol. Chem. 273:1998;12101-12108.
85. Zwiisen R.M.L., Buckle R.S., Hijmans E.M., Loomans C.J.M., Bernards R. Ligand-independent recruitment of steroid receptor coactivators to estrogen receptor by cyclin D1. Genes Devel. 12:1998;3488-3498.
86. Lanz R.B., McKenna N.J., Onate S.A.et al. A steroid receptor coactivator, SRA, functions as an RNA and is present in an SRC-1 complex. Cell. 97:1999;17-27.
87. Voegel J.J., Heine M.J.S., Zechel C., Chambon P., Gronemeyer H. TIF2, a 160 kDa transcriptional mediator for the ligand-dependent activation function AF-2 of nuclear receptors. EMBO J. 15:1996;3667-3675.
88. Kamei Y., Xu L., Heinzel T.et al. A CBP integrator complex mediates transcriptional activation and AP-1 inhibition by nuclear receptors. Cell. 85:1996;403-414.
89. Hanstein B., Eckner R., DiRenzo J.et al. P300 is a component of an estrogen receptor coactivator complex. Proc. Natl. Acad. Sci. USA. 93:1996;11540-11545.
90. Chakravarti D., LaMorte V.J., Nelson M.C.et al. Role of CBP/p300 in nuclear receptor signalling. Nature. 383:1996;99-103.
91. Spencer T.E., Jenster G., Burcin M.M.et al. Steroid receptor coactivator-1 is a histone acetyltransferase. Nature. 389:1997;194-198.
92. Lieberman M.E., Gorski J., Jordan V.C. An estrogen receptor model to describe the regulation of prolactin synthesis by antiestrogens in vitro. J. Biol. Chem. 258:1983;4741-4745.
93. Tate A.C., Greene G.L., DeSombre E.R., Jensen E.V., Jordan V.C. Differences between estrogen and antiestrogen-estrogen receptor complexes identified with an antibody raised against the estrogen receptor. Cancer Res. 44:1984;1012-1018.
94. Jordan V.C., Lieberman M.E. Estrogen-stimulated prolactin synthesis in vitro. classification of agonists, partial agonist and antagonist actions based on structure Mol. Pharmacol. 26:1984;274-285.
95. Belleau B. A molecular theory of drug action based on induced conformational perturbations of receptors. J. Med. Chem. 7:1964;776-778.
96. McDonnell D.P., Clemm D.L., Herman T., Goldman M.E., Pike J.W. Analysis of estrogen receptor function reveals three distinct classes of antiestrogens. Mol. Endocrinol. 9:1995;659-669.
97. Katzenellenbogen J.A., O'Malley B.W., Katzenellenbogen B.S. Tripartite steroid receptor pharmacology. interaction with multiple effector sites as a basis for the cell- and promoter-specific action of these hormones Mol. Endocrinol. 10:1996;119-131.
98. Webster N.J., Green S., Jin J.R., Chambon P. The hormone-binding domains of the estrogen and glucocorticoid receptors contain an inducible transcription activation function. Cell. 54:1988;199-207.
99. Gronemeyer H., Benhamou B., Berry M.et al. Mechanisms of antihormone action. J. Steroid Biochem. Mol. Biol. 41:1992;217-221.
100. McInerney E.M., Katzenellenbogen B.S. Different regions in activation function-1 of human estrogen receptor required for antiestrogen- and estradiol-dependent transcriptional activation. J. Biol. Chem. 271:1996;24172-24178.
101. Metzger D., Berry M., Ali S., Chambon P. Effect of antagonists on DNA binding properties of the human estrogen receptor in vitro and in vivo. Mol. Endocrinol. 9:1995;579-591.
102. Horlein A.J., Naar A.M., Heinzel T.et al. Ligand-independent repression by the thyroid hormone receptor mediated by a nuclear receptor co-repressor. Nature. 377:1995;397-403.
103. Kurokawa R., Soderstrom M., Horlein A.et al. Polarity-specific activities of retinoic acid receptors determined by a co-repressor. Nature. 377:1995;451-454.
104. Chen J.D., Evans R.M. A transcriptional corepressor that interacts with nuclear hormone receptors. Nature. 377:1995;454-457.
105. Levenson A.S., Tonetti D.A., Jordan V.C. The estrogen-like effect of 4-hydroxytamoxifen on induction of transforming growth factor α mRNA in MDA-MB-231 breast cancer cells stably expressing the estrogen receptor. Br. J. Cancer. 77:1998;1812-1819.
106. Levenson A.S., Catherino W.H., Jordan V.C. Estrogenic activity is increased for an antiestrogen by a natural mutation of the estrogen receptor. J. Steroid Biochem. Mol. Biol. 60:1997;261-268.
107. Levenson A.S., Jordan V.C. The key to the antiestrogenic mechanism of raloxifene is amino acid 351 (aspartate) in the estrogen receptor. Cancer Res. 58:1998;1872-1875.
108. Black L.J., Sato M., Rowley E.R.et al. Raloxifene (LY139481 HCI) prevents bone loss and reduces serum cholesterol without causing uterine hypotrophy in ovariectomized rats. J. Clin. Invest. 93:1994;63-69.
109. Boss S.M., Huster W.J., Neild J.A., Glant M.D., Eisenhut C.C., Draper M.W. Effect of raloxifene hydrochloride on the endometrium of postmenopausal women. Am. J. Obstet. Gynecol. 177:1997;1458-1464.
110. Howell A., Defriend D., Robertson J., Blarney R., Walton P. Response to a specific antioestrogen (ICI 182,780) in tamoxifen-resistant breast cancer. Lancet. 345:1995;29-30.
111. Dauvois S., White R., Parker M.G. The antiestrogen ICI 182,780 disrupts estrogen receptor nucleocytoplasmic shuttling. J. Cell Sci. 106:1993;1377-1388.
112. Love R.R., Wiebe D.A., Newcomb P.A.et al. Effects of tamoxifen on cardiovascular risk factors in postmenopausal women. Ann. Intern. Med. 115:1991;860-864.
113. Walsh B.W., Kuller L.H., Wild R.A.et al. Effects of raloxifene on serum lipids and coagulation factors in healthy postmenopausal women. JAMA. 279:1998;1445-1451.
114. Dana S.L., Hoener P.A., Wheeler D.A., Lawerence C.B., McDonnell D.P. Novel estrogen response elements identified by genetic selection in yeast are differentially responsive to estrogens and antiestrogens in mammalian cells. Mol. Endocrinol. 8:1994;1193-1207.
115. Yang N.N., Venugopalan M., Hardikar S., Glasebrook A. Identification of an estrogen response element activated by metobolite of 17β estradiol and raloxifene. Science. 273:1996;1222-1225.
116. Yang N.N., Venugopalan M., Hardikar S., Glasebrook A. Correction. Raloxifene response needs more than an element. Science. 275:1997;1249.
117. Speirs V., Parkes A.T., Kerin M.J.et al. Coexpression of estrogen receptor α and β poor prognostic factors in human breast cancer Cancer Res. 59:1999;525-528.
118. Dotzlaw H., Leygue E., Watson P.H., Murphy L.C. Estrogen receptor-β messenger RNA expression in human breast tumor biopsies. relationship to steroid receptor status and regulation by progestins Cancer Res. 59:1999;529-532.
119. Rauschning W., Pritchard K.I. Droloxifene, a new antiestrogen. its role in metastatic breast cancer Breast Cancer Res. Treat. 31:1994;83-94.
120. Ke H.Z., Simmons H.A., Pirie C.M., Crawford D.T., Thompson D.D. Droloxifene, a new estrogen antagonist/agonist, prevents bone loss in ovariectomized rats. Endocrinology. 136:1995b;2435-2440.
121. Willson T.M., Norris J.D., Wagner B.L.et al. Dissection of the molecular mechanism of action of GW5638, a novel estrogen receptor ligand, provides insights into the role of estrogen receptor in bone. Endocrinology. 138:1997;3901-3911.
122. Ke H.Z., Paralkar V.M., Grasser W.A.et al. Effects of CP-336,156, a new, nonsteroidal estrogen agonist/antagonist, on bone, serum cholesterol, uterus and body composition in rat models. Endocrinology. 139:1998;2068-2076.
123. Sato M., Turner C.H., Wang T., Adrian M.D., Rowley E., Bryant H.U. LY353381.HCl. a novel raloxifene analog with improved SERM potency and efficacy in vivo J. Pharmacol. Exp. Ther. 287:1998;1-7.
124. Gauthier S., Caron B., Cloutier J.et al. (S)-(+)-[4-[7-(2,2-dimethyl-1-oxopropoxy)-4-methyl-2-[4-[2-(1-piperidinyl) ethoxy]phenyl]-2H-1-benzopyran-3-yl]phenyl]-2,2-dimethylpropanoate (EM-800). a highly potent, specific and orally active non-steroidal antiestrogen J. Med. Chem. 40:1997;2117-2122.
125. MacGregor JI, Liu H, Tonetti DA, Jordan VC. The interaction of raloxifene and the active metabolite of the antiestrogen EM-800 with the human estrogen receptor (ER). Cancer Res 1999, 59, 4308-4313.
126. Baumler E. Paul Ehrlich - Scientist for Life. 1984;Holmes and Meier, New York.
127. Schrek R. Fashions in cancer research. Wartman W.B. Year Book of Pathology and Clinical Pathology. 1960;26-39 Year Book Publishers, Chicago.
128. Lerner L.J., Holthaus J.F., Thompson C.R. A nonsteroidal estrogen antagonist 1-(p-2 diethylaminoethoxyphenyl)-1-phenyl-2-p-methoxyphenyl-ethanol. Endocrinology. 63:1958;295-318.
129. Lerner L.J. The first non-steroidal antiestrogen- MER 25. Sutherland R.L., Jordan V.C. Nonsteroidal Antioestrogens. Molecular Pharmacology and Antitumour Activity:1981;1-6 Sydney Academic Press, Sydney, Australia.
130. Jordan V.C. The development of tamoxifen for breast cancer. a tribute to the late Arthur L. Walpole Breast Cancer Res. Treat. 11:1988;197-209.
131. Sporn M.B., Dunlop N.M., Newton D.L., Smith J.M. Prevention of chemical carcinogenesis by vitamin A and its synthetic analogs (retinoids). Fed. Proc. 35:1976;1332-1338.
132. Sporn M.B. Approaches to prevention of epithelial cancer during the preneoplastic period. Cancer Res. 36:1976;2699-2702.
133. Lerner L.J., Jordan V.C. Development of antiestrogens and their use in breast cancer. B.F. Cain Memorial Lecture. Cancer Res. 50:1990;4177-4189.
134. Jordan V.C., Morrow M. Tamoxifen, raloxifene, and the prevention of breast cancer. Endocrine Rev. 20:1999;253-278.
135. Sun J., Meyers J.M., Bink B.E., Rajendran R., Katzenellenbogen J.A., Katzenellenbogen B.S. Novel ligands that function as selective estrogens or antiestrogens for estrogen receptor-α or estrogen receptor-β Endocrinol. 140:1999;800-804.